
Our work helps change lives
Impact of Prostate Specific Antigen-Levels on Survival Outcomes with PROVENGE
Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
Survival Outcomes with PROVENGE in a Placebo-controlled, Randomized Phase 3 study
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Demonstration of PROVENGE-Activated Immune Cells Killing Other Cells that Have Prostate Cancer Antigens in vitro
Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
A Review Describing the Mechanism of Action of PROVENGE
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
PROVENGE Activation of Immune Function Is Related to Overall Survival in Patients with Advanced Prostate Cancer
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Treatment with PROVENGE® in Medicare Beneficiaries with Advanced Prostate Cancer
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
Effects of Race on Real-World Outcomes with PROVENGE in Patients with Advanced Prostate Cancer
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
Real-World Outcomes with PROVENGE in Patients with Advanced Prostate Cancer
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer